Antibiotic Action Fund Remains Stop-Gap As Industry Waits For Reimbursement Legislation

 
• By Joseph Haas

Pharma-backed investment fund to combat antimicrobial resistance aims to find Phase II-ready programs, but can’t generate a constant flow of innovation without better ‘pull’ incentives, industry says.

3d illustration Bacteria E. Coli
E Coli can bide its time. Can we? • Source: iStock / Getty Images Plus (Design Cells/Getty Images/iStockphoto)

More from Market Access

More from Pink Sheet